Yes, hydroxychloroquine (HCQ) can and should be given to patients with systemic lupus erythematosus and intracranial hypertension.
HCQ is recommended for all patients with SLE regardless of organ manifestations, including those with neuropsychiatric involvement such as intracranial hypertension. 1 The presence of intracranial hypertension is not a contraindication to HCQ use.
Rationale for HCQ Use in This Population
The 2019 EULAR guidelines explicitly state that hydroxychloroquine is recommended for all patients with SLE 1. This universal recommendation is based on multiple benefits:
- Prevention of disease flares - HCQ reduces flare rates by 2.5-fold 2
- Reduction in organ damage accrual - Including neurological damage 3
- Improved long-term survival 2
- Reduced cardiovascular risk 1
- Lower glucocorticoid requirements 1
The 2024 KDIGO guidelines reinforce this, noting that HCQ prevents SLE flares and increases long-term patient survival with infrequent, mild, and usually reversible toxicity 2.
Dosing Considerations
Use 5 mg/kg/day based on actual body weight, not to exceed this threshold 1, 4. The 2019 EULAR guidelines specifically note that doses below 5 mg/kg real body weight have very low toxicity risk 1. While earlier studies used 6.5 mg/kg/day, the current consensus prioritizes the 5 mg/kg/day threshold to minimize retinal toxicity 4.
For practical dosing:
- Most patients receive 200 mg daily (one tablet)
- Recent data suggest stable doses of 200 mg/day achieve prolonged remission in 72% of patients 5
- Do not reduce below therapeutic levels - doses of 2-3 mg/kg/day may not achieve adequate blood levels and increase flare risk 2
Specific Considerations for Intracranial Hypertension
The 2010 EULAR recommendations for neuropsychiatric SLE do not list intracranial hypertension as a contraindication to HCQ 6. In fact, a recent 2025 case report describes successful treatment of IIH as an initial SLE manifestation using HCQ as part of the therapeutic regimen alongside corticosteroids and immunosuppressants 7.
Key management points:
- HCQ should be started immediately as background therapy
- Combine with appropriate treatment for intracranial hypertension (acetazolamide, corticosteroids)
- Monitor for papilledema resolution with ophthalmology follow-up
- The ophthalmologic monitoring required for IIH actually facilitates the retinal screening needed for HCQ safety
Safety Monitoring Required
Ophthalmologic screening protocol 2, 4:
- Baseline examination is not required per 2020 Royal College of Ophthalmologists guidelines 2
- Begin annual screening after 5 years of therapy in standard-risk patients
- Begin screening after 1 year if additional risk factors present:
- eGFR <60 mL/min/1.73 m²
- Concomitant tamoxifen use
- Dose >5 mg/kg/day
The presence of intracranial hypertension requiring ophthalmologic monitoring is actually advantageous - these patients will already have regular eye examinations that can incorporate HCQ retinal toxicity screening.
Absolute Contraindications
The only absolute contraindication to HCQ in adult SLE patients is pre-existing retinal toxicity from HCQ 8. Other rare contraindications include:
- Known hypersensitivity to 4-aminoquinolines
- Pre-existing maculopathy (relative contraindication requiring careful risk-benefit assessment) 9, 4
Intracranial hypertension is not among these contraindications.
Dose Adjustments
Renal impairment: If eGFR <30 mL/min/1.73 m², reduce HCQ dose by 25% 3, 2. Check renal function given the association between SLE and lupus nephritis.
Do not discontinue HCQ without compelling reason - withdrawal significantly increases relapse risk, with severe flares occurring up to 6 times more frequently 10. Even in patients who develop retinopathy requiring HCQ discontinuation, the relapse rate increases substantially (31.3% vs 12.5%, OR=3.1) 10.
Clinical Pitfalls to Avoid
- Do not withhold HCQ due to neuropsychiatric manifestations - there is no evidence that HCQ worsens intracranial hypertension
- Do not use subtherapeutic doses - doses below 3 mg/kg/day are associated with higher flare rates 2
- Do not skip HCQ monitoring - blood levels below 200 ng/mL indicate poor adherence and correlate with 80% missed-dose rates 10
- Do not delay initiation - HCQ takes weeks to months to reach steady-state blood levels, so early initiation is critical 1